Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.32 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.32 |
| ▸ | EDNRB | P24530 | 1/20 | 0.31 |
| ▸ | EDNRA | P25101 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20013700 | 0.75 | CASR (0.33) | MAPTALDH1A1KMT2ASMN1; SMN2TP53 | |
| SCHEMBL19998187 | 0.73 | OGA (0.44) | MAPTALDH1A1KMT2ATP53 | |
| SCHEMBL25843255 | 0.72 | ESR1 (0.32) | EDNRBEDNRA | |
| SCHEMBL29910923 | 0.72 | MAPT (0.58) | MAPTALDH1A1GRIA1CACNG8 | |
| SCHEMBL4569783 | 0.72 | MAPT (0.58) | MAPTALDH1A1GRIA1CACNG8 | |
| SCHEMBL7448049 | 0.71 | ALDH1A1 (0.43) | MAPTALDH1A1KMT2ASMN1; SMN2TP53 | |
| SCHEMBL13969591 | 0.69 | ALDH1A1 (0.48) | MAPTALDH1A1KMT2ASMN1; SMN2POLB | |
| SCHEMBL12658621 | 0.67 | SMN1; SMN2 (0.44) | MAPTALDH1A1KMT2ASMN1; SMN2POLB | |
| SCHEMBL18762866 | 0.67 | CYP2D6 (0.36) | ALDH1A1SMN1; SMN2TDP1EDNRBEDNRA | |
| SCHEMBL13085751 | 0.66 | ALDH1A1 (0.34) | ALDH1A1SMN1; SMN2TDP1EDNRBEDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572367-B2 | Antiviral heterocyclic compounds | ENANTA PHARMACEUTICALS, INC. (US) | 2023-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572367-B2 | Antiviral heterocyclic compounds | ACE, HPRT1, ACE2 | MAPT 4608/4885ALDH1A1 2176/4885KMT2A 2570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.